Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vistin Pharma ASA (VISTN) Fair Value & Analysis

Healthcare · NO · Market cap 931M NOK

Pricekr 20.80
Fair Valuekr 33.21
Upside+59.7%
Quality95/100
Evidence: High Range kr 19.40 – kr 43.27

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Vistin Pharma ASA (VISTN) currently trades at kr 20.80, while our model-based Fair Value estimate is kr 33.21 — implying the stock looks roughly 59.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Vistin Pharma ASA (VISTN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 33.21 versus a price of kr 20.80 — about +60% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VISTN?
Our 21-model fair value for Vistin Pharma ASA is kr 33.21 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 20.80.
What is the quality score of VISTN?
Vistin Pharma ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.